GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nyrada Inc (ASX:NYR) » Definitions » Short-Term Debt

Nyrada (ASX:NYR) Short-Term Debt : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Nyrada Short-Term Debt?

Nyrada's Short-Term Debt for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Nyrada Short-Term Debt Historical Data

The historical data trend for Nyrada's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyrada Short-Term Debt Chart

Nyrada Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
Short-Term Debt
- - - - -

Nyrada Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Short-Term Debt Get a 7-Day Free Trial - - - - -

Nyrada Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Nyrada Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Nyrada's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Nyrada (ASX:NYR) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nyrada Inc (ASX:NYR) » Definitions » Short-Term Debt
Comparable Companies
ASX:ANR ASX:HXL ASX:EX1 ASX:RGS ASX:NC6 ASX:ILA ASX:NSB ASX:1AD ASX:ZLD ASX:MEM OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
828 Pacific Highway, Suite 2, Level 3, Gordon, NSW, AUS, 2072
Website
https://www.nyrada.com
Nyrada Inc is a preclinical-stage, drug discovery, and development company, specializing in novel small-molecule drugs to treat cardiovascular and neurological diseases. The company's two programs center on cholesterol-lowering and brain injury, each targeting market sectors of notable size and unmet clinical needs. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury.

Nyrada (ASX:NYR) Headlines

No Headlines